Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03679949

Enrollment

Registered

2018-09-21

Start date

2019-04-01

Completion date

2022-12-06

Last updated

2024-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abuse, Drug, Pain

Keywords

experimental pain, Cannabis, Cannabidiol, THC

Brief summary

The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.

Interventions

DRUGOxycodone

Oxycodone, 2.5 mg

DRUGCannabis (THC:CBD = ~ 1:0)

Cannabis with high THC concentration and negligible CBD concentrations

DRUGCannabis (THC:CBD = ~ 0:1)

Cannabis with high CBD concentration and negligible THC concentrations

DRUGCannabis (THC:CBD = ~ 1:1)

Cannabis with equivalent CBD and THC concentrations

DRUGPlacebo

Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Intervention model description

This is a randomized, cross-over, double-blind, placebo-controlled study. All participants will partake in each arm and receive all interventions.

Eligibility

Sex/Gender

ALL

Age

21 Years to 53 Years

Healthy volunteers

Yes

Inclusion criteria

* Male or non-pregnant female aged 21-53 years * Previous cannabis use * Previous opioid use * Urine test positive for recent cannabis use * Being able to perform all study procedures * Currently practicing an effective form of birth control (women only)

Exclusion criteria

* Meeting criteria for some Use Disorders * Report regular illicit drug use * If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process revealed any significant illness

Design outcomes

Primary

Measure	Time frame	Description
Subjective Effects	6 weeks	Participants will rate drug liking, good drug effects, and high on a visual analogue scale (VAS; 1-100mm).
Cold Pressor Test	6 weeks	Participants will immerse their hand in a bucket of ice water to determine pain threshold and pain tolerance latencies (in seconds).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026